NCT05702034Active, not recruitingPhase 3
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
Janssen Research & Development, LLC880 sites in 1 country12,523 target enrollmentStarted: February 15, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Active, not recruiting
- Enrollment
- 12,523
- Locations
- 880
- Primary Endpoint
- Time to First Occurrence of Ischemic Stroke
Study Overview
Brief Summary
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Ischemic Stroke: a neurological deficit attributable to an acute brain infarction and national institute of health stroke score scale (NIHSS) score less than or equal to (<=) 7 and at least 1 of the following: persistent signs or symptoms of the ischemic event at the time of randomization, or acute, ischemic brain lesion determined by standard-of-care neuroimaging, or participant underwent thrombolysis or thrombectomy, or transient ischemic attack (TIA): acute onset neurological deficit attributable to focal ischemia of the brain by history or examination, with complete symptom resolution of the deficit and no brain infarction on neuroimaging (example, computed tomography (CT) scan or magnetic resonance imaging (MRI), performed as part of standard medical practice), and ABCD2 Score greater than or equal to (>=) 6
- •Participants will be randomized as soon as possible after determining eligibility and within 48 hours of onset of event.
- •Current or planned antiplatelet treatment per international and/or local guidelines. If acetyl salicylic acid (ASA) is used, it will be limited to low dose (75 to 100 milligrams (mg)/day). Loading dose of antiplatelet agents (including ASA) are allowed per standard-of-care
- •A female participant must agree not to be pregnant, breastfeeding, or planning to become pregnant until 4 days (5 half lives) after the last dose of study intervention
- •Willing and able to adhere to the lifestyle restrictions specified in this protocol
Exclusion Criteria
- •Prior history of intracranial hemorrhage except subarachnoid hemorrhage greater than (>) 1 year prior with adequate treatment
- •The index stroke or TIA is considered to have a cardio-embolic etiology based on local standard-of-care investigations and for which guidelines recommend anticoagulation
- •The index stroke or TIA considered to have another known cause, not related to athero-thrombotic sources (treatment of acute stroke trial [TOAST] Other Determined Etiology), based on local standard-of-care investigations
- •Increased risk of bleeding, including clinically significant bleeding within the previous 3 months or known bleeding diathesis or known activated partial thromboplastin time (aPTT) prolongation or spinal cord hemorrhage or retinal hemorrhage
- •Current active liver disease, eg, acute hepatitis, known cirrhosis, including participants receiving antiviral treatment for hepatitis
- •Known allergies, hypersensitivity, or intolerance to milvexian or its excipients
Arms & Interventions
Placebo
Placebo Comparator
Participants after an acute ischemic stroke or high-risk TIA who are receiving antiplatelet therapy standard-of-care (SAPT or DAPT) will receive placebo orally twice daily.
Intervention: Placebo (Drug)
Milvexian
Experimental
Participants after an acute ischemic stroke or high-risk transient ischemic attack (TIA) who are receiving antiplatelet therapy standard-of-care (SAPT [single antiplatelet therapy] or DAPT [dual antiplatelet therapy]) will receive milvexian 25 milligrams (mg), orally, twice daily.
Intervention: Milvexian (Drug)
Outcomes
Primary Outcomes
Time to First Occurrence of Ischemic Stroke
Time Frame: Up to global targeted endpoint date (approximately 41 months)
Time to first occurrence of ischemic stroke will be reported.
Secondary Outcomes
- Time to First Occurrence of any Component of the Composite of Cardiovascular Death (CVD), Myocardial Infraction (MI), or Ischemic Stroke(Up to global targeted endpoint date (approximately 41 months))
- Time to First Occurrence of any Component of Major Adverse Vascular Events (MAVE)(Up to global targeted endpoint date (approximately 41 months))
- Time to First Occurrence of Ischemic Stroke(Up to Day 90)
Investigators
Study Sites (880)
Loading locations...
Similar Trials
Completed
Phase 3
A Study of Milvexian in Participants After a Recent Acute Coronary SyndromeAcute Coronary SyndromeNCT05754957Janssen Research & Development, LLC14,194
Active, not recruiting
Phase 3
A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationAtrial FibrillationNCT05757869Janssen Research & Development, LLC20,284
Completed
Phase 1
A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy ParticipantsHealthyNCT04543383Janssen Research & Development, LLC52
Completed
Phase 3
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerTriple Negative Breast CancerNCT02032277AbbVie634
Completed
Phase 3
PPAR - Combination With MetforminDiabetes MellitusNCT00162240Bristol-Myers Squibb534